INVA Innoviva, Inc.
QT70Latest market price
21.22
-0.09-0.42%
TA
Loading chart...
Snapshot
| Index | — | P/E | 5.18 | EPS (ttm) | 4.10 | Insider Own | — | Shs Outstand | 72.25M | Perf Week | 2.71% |
| Market Cap | 1.53B | Forward P/E | 9.38 | EPS next Y | 2.26 | Insider Trans | 0.00% | Shs Float | 67.65M | Perf Month | 3.26% |
| Enterprise Value | 1.22B | PEG | — | EPS next Q | 0.52 | Short Float | 10.74% | Perf Quarter | 2.17% | ||
| Income | 358.00M | P/S | 3.45 | EPS this Y | 27.31% | Short Ratio | 9.28 | Perf Half Y | -8.18% | ||
| Sales | 444.00M | P/B | 1.24 | EPS next Y | -6.53% | ROA | 20.98% | Short Interest | 7.27M | Perf YTD | 6.15% |
| Book/sh | 17.07 | P/C | 2.65 | EPS next 5Y | -5.01% | ROE | 30.03% | 52W High | 25.15 -15.63% | Perf Year | 20.77% |
| Cash/sh | 8.01 | P/FCF | 8.11 | EPS past 3/5Y | 11.67% 10.31% | ROIC | 8.36% | 52W Low | 17.53 21.05% | Perf 3Y | 67.88% |
| Dividend Est. | — | EV/EBITDA | 1.59 | Sales past 3/5Y | 8.69% 4.75% | Gross Margin | 73.09% | Volatility | 1.99% 2.09% | Perf 5Y | 30.67% |
| Dividend TTM | — | EV/Sales | 2.75 | EPS Y/Y TTM | 1317.21% | Oper. Margin | 36.66% | ATR (14) | 0.47 | Perf 10Y | 108.24% |
| Dividend Ex-Date | Sep 08, 2015 | Quick Ratio | 15.18 | Sales Y/Y TTM | 19.68% | Profit Margin | 80.56% | RSI (14) | 53.40 | Recom | 2.60 |
| Dividend Gr. 3/5Y | — | Current Ratio | 16.01 | EPS Q/Q | 48.05% | SMA20 | 1.04% | Beta | 0.38 | Target Price | 38.00 |
| Payout | 0.00% | Debt/Eq | 0.22 | Sales Q/Q | 20.00% | SMA50 | 1.10% | Rel Volume | 0.80 | Prev Close | 21.31 |
| Employees | 159 | LT Debt/Eq | 0.22 | Earnings | Nov 04 | SMA200 | -3.05% | Avg Volume | 777.14K | Price | 21.22 |
| IPO Date | Oct 05, 2004 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 161.47% 7.75% | Net Debt/EBITDA | -0.40 | Volume | 623,266 | Change | -0.42% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Cantor Fitzgerald | Overweight | $32 → $34 |
| May-07-26 | Reiterated | BTIG | Buy | $35 → $42 |
| Feb-26-26 | Reiterated | Cantor Fitzgerald | Overweight | $32 |
| Feb-17-26 | Initiated | BTIG | Buy | $35 |
| Dec-16-25 | Reiterated | HC Wainwright & Co. | Buy | $46 |
| Sep-30-25 | Initiated | Goldman Sachs | Sell | $17 |
| Aug-11-25 | Initiated | Oppenheimer | $35 | |
| Mar-07-25 | Initiated | Scotiabank | Outperform | $55 |
| Aug-08-22 | Reiterated | Morgan Stanley | Underweight | $12 → $13 |
| Jul-15-22 | Reiterated | Morgan Stanley | Underweight | $12 |
Latest News· Times ET
Oct-27-26
Oct-20-26
Oct-20-2606:50AM
Oct-19-26
Oct-19-2608:00AM
Oct-12-26
Oct-08-26
12:40PM
10:41AM
Oct-05-26
Sep-25-26
Sep-23-26
Sep-17-26
Sep-17-2605:11AM
Sep-16-26
Sep-16-2601:29AM
Sep-15-26
Sep-15-2603:29AM
Sep-08-26
Company
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 444 | 425 | 359 | 310 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 119 | 118 | 37 | 43 | — | — | — | — | — | |
| Gross Profit | 325 | 308 | 322 | 268 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 126 | 113 | 116 | 98 | — | — | — | — | — | |
| Research and Development | 29 | 31 | 14 | 34 | — | — | — | — | — | |
| Other Operating Expense | 7 | 0 | 25 | 22 | — | — | — | — | — | |
| Operating Income | 163 | 164 | 167 | 114 | — | — | — | — | — | |
| Interest Expense | 17 | 17 | 22 | 19 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 275 | 180 | -107 | 99 | — | — | — | — | — | |
| Net Income Before Taxes | 420 | 327 | 37 | 194 | — | — | — | — | — | |
| Income Taxes | 62 | 56 | 14 | 14 | — | — | — | — | — | |
| Consolidated Net Income | 358 | 271 | 23 | 180 | — | — | — | — | — | |
| Net Income From Continuing Operations | 358 | 271 | 23 | 180 | — | — | — | — | — | |
| Net Income | 358 | 271 | 23 | 180 | — | — | — | — | — | |
| EPS (Recurring) | 4.87 | 4.02 | 0.37 | 2.92 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 4.87 | 4.02 | 0.37 | 2.92 | — | — | — | — | — | |
| EPS (Diluted) | 4.10 | 3.30 | 0.36 | 2.20 | — | — | — | — | — | |
| EBITDA | 769 | 384 | 99 | 249 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 5.18 | 6.06 | 48.19 | 7.29 | — | — | — | — | — | |
| Price To Sales Ratio | 3.49 | 3.15 | 3.04 | 3.36 | — | — | — | — | — | |
| Gross Margin | 73.20 | 72.47 | 89.69 | 86.45 | — | — | — | — | — | |
| Operating Margin | 36.71 | 38.59 | 46.52 | 36.77 | — | — | — | — | — | |
| Net Margin | 80.63 | 63.76 | 6.41 | 58.06 | — | — | — | — | — | |
| Shares Outstanding | 73 | 67 | 63 | 65 | — | — | — | — | — | |
| Market Capitalization | 1,549 | 1,339 | 1,093 | 1,043 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| DENNER ALEXANDER J | 10% Owner | Mar 06 '25 | Sale | 17.52 | 1,196,746 | 20,964,237 | 5,658,705 | Mar 06 |
| DENNER ALEXANDER J | 10% Owner | Mar 05 '25 | Sale | 17.63 | 270,374 | 4,766,126 | 6,855,451 | Mar 06 |
| DENNER ALEXANDER J | 10% Owner | Mar 04 '25 | Sale | 17.63 | 151,175 | 2,665,079 | 7,125,825 | Mar 06 |
| Zhen Marianne | Chief Accounting Officer | Nov 15 '23 | Sale | 13.99 | 10,994 | 153,810 | 40,158 | Nov 17 |
| DENNER ALEXANDER J | 10% Owner | Jun 15 '23 | Buy | 13.13 | 62,000 | 814,196 | 7,277,000 | Jun 20 |
| DENNER ALEXANDER J | 10% Owner | Jun 06 '23 | Buy | 13.05 | 8,000 | 104,384 | 7,215,000 | Jun 07 |
| DENNER ALEXANDER J | 10% Owner | Jun 05 '23 | Buy | 13.04 | 7,000 | 91,297 | 7,207,000 | Jun 07 |
| DENNER ALEXANDER J | 10% Owner | May 30 '23 | Buy | 13.01 | 120,000 | 1,560,648 | 7,200,000 | May 30 |
| DENNER ALEXANDER J | 10% Owner | May 26 '23 | Buy | 13.12 | 30,000 | 393,729 | 7,080,000 | May 30 |
| DENNER ALEXANDER J | 10% Owner | May 25 '23 | Buy | 13.09 | 50,000 | 654,330 | 7,050,000 | May 30 |
| DENNER ALEXANDER J | 10% Owner | May 19 '23 | Buy | 13.48 | 36,000 | 485,147 | 7,000,000 | May 19 |
| DENNER ALEXANDER J | 10% Owner | May 18 '23 | Buy | 13.05 | 10,000 | 130,538 | 6,964,000 | May 19 |
| DENNER ALEXANDER J | 10% Owner | May 17 '23 | Buy | 13.07 | 50,000 | 653,690 | 6,954,000 | May 19 |
| DENNER ALEXANDER J | 10% Owner | May 11 '23 | Buy | 12.34 | 290,000 | 3,577,411 | 6,904,000 | May 15 |
| Raifeld Pavel | Chief Executive Officer | Mar 10 '23 | Buy | 10.87 | 3,000 | 32,603 | 9,799 | Mar 14 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.